JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

(2020) Heinz Gisslinger et al.   Lancet Haematology

How I treat polycythemia vera

(2019) Jerry L. Spivak   BLOOD

Oral Idasanutlin in Patients with Polycythemia Vera

(2019) John Mascarenhas et al.   BLOOD

Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations

(2019) Rebecca J. Austin et al.   LEUKEMIA

Oral arsenic and all-transretinoic acid for high-risk acute promyelocytic leukemia

(2018) Hong-Hu Zhu et al.   BLOOD

PML nuclear bodies: from architecture to function

(2018) Valérie Lallemand-Breitenbach et al.   CURRENT OPINION IN CELL BIOLOGY

PML: Regulation and multifaceted function beyond tumor suppression

(2018) Kuo-Sheng Hsu et al.   Cell and Bioscience

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

(2018) Emmanuelle Verger et al.   Blood Cancer Journal

PML is a ROS sensor activating p53 upon oxidative stress

(2017) Michiko Niwa-Kawakita et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A PML/Slit Axis Controls Physiological Cell Migration and Cancer Invasion in the CNS

(2017) Valeria Amodeo et al.   Cell Reports

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms

(2016) William Vainchenker et al.   BLOOD

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

(2015) J-J Kiladjian et al.   LEUKEMIA

PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence

(2015) Lisa Ivanschitz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon   2a target JAK2V617F-positive progenitor and stem cells

(2014) M. Lu et al.   BLOOD

Complete senescence: RB and PML share the task

(2014) Mathieu Vernier et al.   CELL CYCLE

Myeloproliferative Neoplasms: JAK2 Signaling Pathway as a Central Target for Therapy

(2014) Florence Pasquier et al.   Clinical Lymphoma Myeloma & Leukemia

Cytokine combinations on the potential for ex vivo expansion of murine hematopoietic stem cells

(2014) Wing Chi Lui et al.   CYTOKINE

Oxidative stress–induced assembly of PML nuclear bodies controls sumoylation of partner proteins

(2014) Umut Sahin et al.   JOURNAL OF CELL BIOLOGY

Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure

(2014) Julien Ablain et al.   NATURE MEDICINE

Resistance to Therapy in Acute Promyelocytic Leukemia

(2014) Jacqueline Lehmann-Che et al.   NEW ENGLAND JOURNAL OF MEDICINE

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-  in a murine model of polycythemia vera

(2013) A. Mullally et al.   BLOOD

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN 

(2013) S. Hasan et al.   BLOOD

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression

(2013) C Marty et al.   LEUKEMIA

Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera

(2012) A. Mullally et al.   BLOOD

Regulation of E2Fs and senescence by PML nuclear bodies

(2011) M. Vernier et al.   GENES & DEVELOPMENT

PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3

(2010) Marion Jeanne et al.   CANCER CELL

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

PML Regulates Apoptosis at Endoplasmic Reticulum by Modulating Calcium Release

(2010) C. Giorgi et al.   SCIENCE

A Senescence-Like Cell-Cycle Arrest Occurs During Megakaryocytic Maturation: Implications for Physiological and Pathological Megakaryocytic Proliferation

(2010) Rodolphe Besancenot et al.   PLOS BIOLOGY

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)

(2009) G. Kchour et al.   BLOOD

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway

(2008) Valérie Lallemand-Breitenbach et al.   NATURE CELL BIOLOGY